Sergey Jakimov is a founding partner of LongeVC, a VC investing in biotech companies and founders. He is a serial entrepreneur, having co-founded 3 deep-tech ventures and raised more than $50M in venture funding. He has advised several other startups in the therapeutics space, and since 2018, he has led the medical tech startup Longenesis (now he is a member board of directors). He is also a board member and co-founder of the Longevity Science Foundation. Sergey is a visiting lecturer at several universities, and he co-authored a master’s program in technology law at the Riga Graduate School of Law. He holds a BSc in International Affairs and two MScs in Political Science and Government and Law and Finance. He was named a Forbes Latvia 30 Under 30 in technology and healthcare in 2020.
LongeVC’s Sergey Jakimov explains why although things look shaky for biotech, a correction phase for longevity can only make it stronger.
Sergey Jakimov discusses how longevity’s ideas are taking root in society, but there is still work to be done to bring healthcare up to speed